Emanuel Petricoin

Emanuel Petricoin is a Professor and Co-Director of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University's School of Systems Biology, a position held since 2005 with prior leadership at the FDA-NCI Clinical Proteomics Program (1993-2005). His academic affiliation spans proteomics, molecular medicine, and precision oncology within GMU's research ecosystem.

His educational background includes:

• Ph.D. in Microbiology from the University of Maryland, College Park (1990)

Dr. Petricoin pioneers clinical proteomics for personalized therapy and biomarker discovery, with seminal work in cancer signaling pathways, tumor microenvironment analysis, and diagnostic assay development. His research integrates proteogenomics, phosphoproteomics, and functional protein analysis to address therapeutic resistance in breast and pancreatic cancers. As a translational scientist, he bridges laboratory innovation with clinical implementation through FDA-regulated platforms.

Analysis of his 2024-2025 publications reveals dominant themes in proteogenomic tumor characterization, KRAS/HER2 pathway dynamics, and biomarker-guided immunotherapy. Key trends include spatial proteomics of tumor heterogeneity, extracellular vesicle-mediated signaling, and quantitative assessment of drug targets for precision oncology decision-making. The work consistently emphasizes clinical applicability through CLIA-certified assays and molecular tumor boards.

His scientific recognition includes:

• University Professorship at George Mason University
• NIH Director’s Award
• FDA Distinguished Scientist Award
• 2015 Innovator of the Year Award
• GAP50 Top Virginia Entrepreneurs
• Nifty 50 Award
• American Society of Cytopathology Basic Research Award
• Roche Diagnostics/CLAS Distinguished Scientist Award
• Harvard University Leading Edge Award

Dr. Petricoin drives research commercialization as co-founder of four biotech firms (Theranostics Health, Ceres Nanosciences, C-4 Diagnostics, Perthera) and co-inventor of 40+ patents. His editorial leadership spans Proteomics, Cancer Epidemiology Biomarkers and Prevention, and other high-impact journals. He actively shapes national initiatives as a HUPO founding member and Virginia Health Research Biosciences Corporation board representative.

The CAPMM under his co-direction serves as a national hub for clinical proteomics, specializing in reverse-phase protein array (RPPA) technology, laser capture microdissection, and biomarker validation for direct patient care applications. The center integrates multi-omic data to advance personalized cancer therapy through industry partnerships and clinical trial support.